---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-008988"
form_type: "8-K"
ticker: "KOD"
cik: "0001468748"
company_name: "Kodiak Sciences Inc."
filed_at: "2022-05-10T23:59:59+00:00"
generated_at: "2026-06-25T21:36:06.073761+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Kodiak Sciences Q1 net loss $95.7M ($1.83/share); updates KSI-301 program after Ph2b/3 miss

## Summary
- Net loss $95.7M ($1.83/share) vs $50.4M ($0.98/share) in Q1 2021.
- R&D expenses $76.2M, up 89% YoY; G&A $19.6M, up 92% YoY; cash $671.7M.
- KSI-301 Phase 2b/3 wet AMD missed primary endpoint; ongoing Phase 3 studies modified to reduce undertreatment risk.
- BEACON top-line data expected August 2022; DAYLIGHT, GLEAM, GLIMMER data mid-2023.
- Commercial manufacturing facility in Visp, Switzerland reached mechanical completion March 2022.

## SEC filing metadata
- accession: 0000950170-22-008988
- form_type: 8-K
- ticker: KOD
- cik: 0001468748
- company_name: Kodiak Sciences Inc.
- filed_at: 2022-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1468748/000095017022008988/0000950170-22-008988-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1468748/000095017022008988/kod-20220510.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-008988
- JSON: https://secwatch.observer/filing/0000950170-22-008988.json
- Plain text: https://secwatch.observer/filing/0000950170-22-008988.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.